

Caltech/MIT Enterprise Forum
VENTURING IN MEDICAL TECHNOLOGIES
March 18, 2003

PRESENTERS

MARK W. KROLL, Ph.D., FACC

818-493-2234

email mkroll@sjm.com

Dr. Kroll is the Senior Vice President and Chief Technology Officer, St. Jude Medical Inc., Cardiac Rhythm Management Division. He began as VP of the Tachycardia Business Unit and has held various VP level positions within St. Jude since 1995. (<http://www.sjm.com>) Previous to that, Dr. Kroll was at Angeion Corp. from 1991 to 1995, most recently as VP of research and product planning.

Dr. Kroll holds a B.S. Mathematics and M.S. and Ph.D. in Electrical Engineering from the University of Minnesota, and an M.B.A. from the University of St. Thomas.

He holds 142 issued U.S. patents and is recognized by the U.S. Patent and Trademark Office as a prolific inventor. He was awarded "Fellow" recognition by the American College of Cardiology (FACC), and is co-author of "**Implantable Cardioverter Defibrillator Therapy**", published by Kluwer of Boston. Dr. Kroll has been listed in Who's Who In Science And Engineering since 1992. He has authored over 75 papers, invited presentations, book chapters, and abstracts.

Dr. Kroll was a co-founder of SurVivaLink which is now the major part of Cardiac Science (DFIB). He is a director of Harbinger Medical, Inc. (cardiac diagnostics), Guidance Interactive, Inc. (diabetes monitoring), Arrowhead Offshore Partners, Ltd (venture capital), and OncoStim, Inc. (DC ablation for cancer).

Dr. Kroll is an annual invited lecturer to the UCLA Anderson School week-long "Creativity and Innovation" program, and an invited speaker to the United States Patent and Trademark Office.

Bragging Points That His Mother Likes:

Dr. Kroll is of a handful of non-MDs – and the only practicing EE - to have been granted the FACC honor. He is the top inventor of implantable medical devices in the world. 99% of the ICDs (Implantable Cardioverter Defibrillator) sold have at least one licensed Kroll patent.

ANTHONY T. MATERNA, Ph.D.

213-626-0927

email tmaterna@pacbell.net

Dr. Materna has 25 years of management experience in large corporations and small enterprises. As an expert on entrepreneurship, he has spoken at numerous forums in the U.S., and as a guest of METI (Ministry of Economics and Trade and Industry) in Japan.

Dr. Materna is the acting President of Tinnitus Mitigation Systems, LLC., and is the President of ACODA Technology and Investments, LLC., specializing in technology transfer to Far East

markets. He holds two U.S. Patents for Computer Integrated System, and for Graphic User Interface for Creating Database Integration specifications.

Dr. Materna obtained his Ph.D. and M.A. degree in Management from the Claremont Graduate School in 1981, and a Masters degree from M.I.T's Sloan School in Industrial Management. In addition he has degrees in Economics and Engineering from Prague University.

PANELISTS

EMILIO FONTANA

310-556-1778

email efontana@LaredGroup.com

Mr. Fontana is the Co-Founder and a Partner of The Lared Group Experience: He has over 30 years of operating and consulting experience at the senior executive level, in all phases of management in diversified multinational corporations.

In his consulting activity over the last thirteen years, Mr. Fontana has successfully directed assignments with entrepreneurial and corporate clients for business alliance formation and remediation, alliance process and competence, strategic plan development and repositioning, formulation and execution of diversification and international expansion plans, joint ventures both domestically and internationally, integration planning and operational improvements, and operation and organization review and restructuring. His clients have included medical device companies and other advanced technology companies.

His line management background includes 17 years with Litton Industries, (4 at Corporate and 13 as an executive of the Sweda International Division).

Mr. Fontana has a degree in Political Science, from the University of Padua, Italy, and a MBA from the Anderson Graduate School of Management, UCLA as a Fulbright Scholar.

FARHAD DAGHIGHIAN, Ph.D.

310-826-9834,

email fd@intra-medical.com

Dr. Daghighian is the founder, President & Chief Scientist of IntraMedical Imaging LLC. IntraMedical Imaging manufactures and markets proprietary nuclear medicine detectors and cameras for use during surgery, laparoscopy, endoscopy, and biopsy. IntraMedical Imaging's instruments have the ability to utilize a broad range of radioisotopes and radiolabeled agents, and provide higher quality information--in the form of real-time images--than the audio counts of the gamma probes.

Dr. Daghighian received a Ph.D. in High Energy Physics from UC Irvine, and postdoctoral training in nuclear medicine and biophysics at the UCLA School of Medicine. Dr. Daghighian is presently an associate member of UCLA's Crump Institute of BioMedical Imaging, and has held a variety of high positions including a position as an Adjunct Research Professor, Radiology Dept. USC, Assistant Professor of Physics in Radiology, Cornell University Medical College, and positions at Sloan-Kettering Institute for Cancer Research. Dr. Daghighian holds numerous patents and has authored nearly 50 papers and abstracts.

ANDREW P. RASDAL

858-812-9600
email arasdal@dexcom.com

Mr. Rasdal is President & CEO of DexCom, Inc., a development-stage company focused on commercializing the first long-term implantable sensor for the continuous measurement of glucose in people with diabetes.

Prior to joining DexCom, Mr. Rasdal was a Corporate Senior Vice President for Medtronic, Inc. and President of Medtronic's Vascular Division with revenues of approximately \$1 billion. Before becoming President, Mr. Rasdal served as Vice President of Medtronic, Inc. and General Manager of Medtronic's Global Coronary Vascular businesses. Mr. Rasdal joined Arterial Vascular Engineering in February 1997 and held the position of Vice President of Marketing prior to its acquisition by Medtronic, Inc. for \$4.3 billion in February 1999. Prior to joining Medtronic, Mr. Rasdal held various positions at EP Technologies, Inc., a start-up that introduced the first approved system for the ablation of cardiac arrhythmias (acquired by Boston Scientific Corporation), SCIMED Lifesystems, Inc. (now Boston Scientific Corporation), and Advanced Cardiovascular Systems, Inc. (now Guidant Corporation).

Mr. Rasdal has a Masters in Management from the Kellogg Graduate School of Business at Northwestern University and a Bachelor of Science degree from San Jose State University.

SHARON STEVENSON, DVM, Ph.D.

949-347-2446
email Stevenson@DomainVC.com

Dr. Stevenson is a principal of Domain Associates, L.L.C. Domain Associates is one of the nation's leading healthcare- and life sciences- focused venture capital groups. Fund performances have consistently been in the top quartile for the industry. Examples of current and past portfolio companies include Align, Amgen, Amylin Pharmaceuticals, Cardiac Sciences, and Proxima Therapeutics. Total capital under management is approximately \$900M. Through the combined financial resources of Domain Partners III, IV, and V, LP, Domain provides \$40-50M annually to U.S.-based ventures in life sciences industry.

As a Principal of Domain Associates, Dr. Stevenson's responsibilities include performing due diligence and advising on investment decisions; providing financial and scientific direction and board input to portfolio companies; and running during their start-up phases new companies that Domain initiates. Dr. Stevenson has held high level positions in companies, including the Executive Director of the NeoCyte Joint Ventures between Advanced Tissue Sciences, Inc. and Smith & Nephew, to develop and commercialize tissue-engineered human cartilage-based products for orthopedic applications.

Dr. Stevenson also has a highly successful academic background, having been an Associate Professor at the Department of Orthopaedics, School of Medicine, Case Western Reserve University; Assistant Professor, Department of Surgery, Tufts University College of Veterinary Medicine; Assistant, Anatomisches Institut, Universitat Bern, Bern Switzerland; Clinical Assistant Professor, the Ohio State University College of Veterinary Medicine.

Dr. Stevenson was the Valedictorian for the 2000 class at UCLA's Anderson School of MBA program, holds a Ph.D. in Comparative Pathology from UC Davis, and a Doctor of Veterinary Medicine (summa cum laude) and a Master of Science in Veterinary Pathobiology from the Ohio State University, College of Veterinary Medicine.

JUDY REAVIS, Ph.D,

781-856-5924, email
ireavis@nelco-usa.com

Dr. Reavis, has a Ph.D. in biophysics, and, as President and CEO of Hermes Systems Management, possesses extensive expertise in regulatory issues, clinical trials, and technology transfer including high-risk medical devices, biologicals, and medical software. She assists and advises international start-ups and most of the major manufacturers of medical devices (Siemens, Philips, GE, Varian, J&J-Cordis, etc), specifically working with executive management, corporate regulatory personnel, attorneys, and the FDA. She conducts due diligence, proforma, and audits on business development of new medical IP, assists with regulatory valuation of behalf of the medical device companies, venture capital firms/investment bankers, attorney, and academic technology transfer offices. With a clinical background in radiation oncology and biophysics, she continues to interact with clinicians in all medical specialties for clinical trials, new biotech developments, and training. While at Siemens AG, Dr. Reavis interfaced with executive management, technical and regulatory staffs in overseeing the company's international research and collaborations between Siemens, with other companies and universities leading to development of new computer-based medical products.

Dr. Reavis has appeared on numerous international radio and television broadcasts as well as newspapers and magazines. She was featured in a BBC documentary on creative ideas and problem solving. She served on an FCC advisory committee for Universal Service (E-Rate) for healthcare and education with budgets of more than a billion dollars per year. Most recently, she has assisted with business development and IP product development for several start-ups that have successfully had IPO's and then acquisition by Fortune 500 companies.

MODERATOR

DAN KIMBELL

626-683-4547

email drk@cph.com

Dan Kimbell is an intellectual property law attorney and registered patent attorney with the Pasadena office of Christie, Parker & Hale, LLP. He practices in the area of domestic and foreign patent and trademark counseling, and IP licensing and prosecution. In the patent field, Dan specializes in a wide variety of technologies, including medical devices, general mechanical devices, chemical, pharmaceutical and nutraceuticals.

Dan's received a B.S. in chemistry from UCLA and his J.D. from Loyola Law School, Los Angeles. Dan is member of the Caltech/MIT Enterprise Forum executive committee.